pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Hympavzi
drug · antibody
save

marstacimab

Marketedupdated 3mo ago
by $PFE PFIZER INC🔗 ChEMBL
Approved
community read0 votes

🐶 often sniffed alongside

top 3
  • tagApproval12 co-mentions · 3 sources
  • drugHYMPAVZI12 co-mentions · 3 sources
  • company$PFEPFIZER INC6 co-mentions · 3 sources

Antibody drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 1 investigational indication.

targets

Tissue factor pathway inhibitor

all catalysts(3)

approval · 3
Oct 11, 2024
approval
$PFE27.79-1.59%
2y ago
HYMPAVZI (MARSTACIMAB-HNCQ) — FDA approval
marstacimab
→
Sep 16, 2025
approval
$PFE27.79-1.59%
11mo ago
HYMPAVZI (MARSTACIMAB-HNCQ) — FDA approval
marstacimab
→
Dec 16, 2025
approval
$PFE27.79-1.59%
8mo ago
HYMPAVZI (MARSTACIMAB-HNCQ) — FDA approval
marstacimab
→

Trials studying marstacimab

  • phase1A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.recruitingn=15
  • phase3A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia Brecruitingn=100
  • —A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.active not recruitingn=50

News(0)

no news has mentioned this drug yet

brand
Hympavzi
trade names
Hympavzi
generic
marstacimab-hncq
MOA
Tissue factor pathway inhibitor inhibitor
indication
Hemophilia A (Factor VIII Deficiency)
phase
marketed
Data sources
openFDA · ClinicalTrials.gov · OpenTargets
last refreshed 8m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?